Manfred Johannsen


Affiliation: Humboldt University
Country: Germany


  1. Johannsen M, Florcken A, Bex A, Roigas J, Cosentino M, Ficarra V, et al. Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis. Eur Urol. 2009;55:1430-8 pubmed publisher
    ..Further investigation in a larger cohort of patients is warranted before such an approach can be regarded as safe. ..
  2. Johannsen M, Gneveckow U, Taymoorian K, Cho C, Thiesen B, Scholz R, et al. [Thermal therapy of prostate cancer using magnetic nanoparticles]. Actas Urol Esp. 2007;31:660-7 pubmed
    ..Until these limitations will be overcome and thermal ablation can safely be applied as a monotherapy, this treatment modality is being evaluated in combination with irradiation in patients with localized prostate cancer. ..
  3. Kempkensteffen C, Fritzsche F, Johannsen M, Weikert S, Hinz S, Dietel M, et al. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer. BMC Cancer. 2009;9:276 pubmed publisher
  4. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S, et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 2008;8:369 pubmed publisher
    ..The frequent up-regulation of FBP1 and FBP3 in urothelial and prostate carcinoma suggests that FBPs also have an important function in gene regulation of these tumors. ..
  5. Tölle A, Jung M, Lein M, Johannsen M, Miller K, Moch H, et al. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?. BMC Cancer. 2009;9:248 pubmed publisher
    ..Further studies should identify the role of both FABPs in carcinogenesis, progression and with regard to a potential target in RCC. ..